Table 3 Cox regression analyses of the three-gene predictive index percentile, as a continuous variable, for 27 patients in the validation set

From: Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

 

Overall survival

Time to progression

 

P-value

HR (95% CI)

P-value

HR (95% CI)

Univariate

 Three-gene predictive index percentilea

0.050

1.015b (1.000–1.030)

0.026

1.017 (1.002–1.031)

Multivariate

 Three-gene predictive index percentile

0.017

1.023 (1.004–1.042)

0.014

1.023 (1.005–1.043)

 Age ⩾70 yearsc

0.027

7.614 (1.257–46.130)

0.144

3.605 (0.646–20.112)

 Poor performance status (ECOG PS 2 or 3)

0.346

2.130 (0.442–10.258)

0.074

4.829 (0.861–27.086)

 Second-line chemotherapy

0.041

4.231 (1.064–16.831)

0.011

5.992 (1.502–23.902)

 Diffuse histological type

0.773

1.164 (0.415–3.263)

0.280

1.774 (0.626–5.025)

  1. Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.
  2. aComputed based on weighted average of log intensities of the three genes (EGFR, FGFR2 and MYC) obtained using a proportional hazards regression on the first two principal components of the log signal intensities of those three genes.
  3. bHR for each percentile increase in three-gene predictive index percentile. For example, a predictive index percentile of 100 (the highest predictive index) is associated with an HR of 4.4 (=1.015100), compared with a predictive index percentile of 0 (the lowest predictive index). The median predictive index (50%) is associated with HRs of 2.1 (=1.01550), compared with the lowest predictive index.
  4. cFor patients aged ⩾70 years, the treatment schedule for fluorouracil could be shortened at the discretion of the oncologist to 3 instead of 5 days.
Back to article page